AI assistant
RELMADA THERAPEUTICS, INC. — Director's Dealing 2021
Apr 5, 2021
34465_dirs_2021-04-05_cb8cb636-85b5-4ea5-b070-d2c27f200e33.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RELMADA THERAPEUTICS, INC. (RLMD)
CIK: 0001553643
Period of Report: 2021-04-01
Reporting Person: CASAMENTO CHARLES J (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-04-01 | Common Stock | S | 1309 | $35.9265 | Disposed | 14641 | Direct |
| 2021-04-01 | Common Stock | S | 1691 | $35.0403 | Disposed | 12950 | Direct |
Footnotes
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020.
F2: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.
F3: Sales prices range from $35.80 to $36.12 per share, inclusive.
F4: Sales prices range from $34.69 to $35.49 per share, inclusive.